Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Corbus Pharmaceuticals has received a consensus recommendation of "Moderate Buy" from ten research firms, with an average 12-month target price of $45.43.
• Despite a strong performance, with shares experiencing a 342% surge YTD, the stock has recently seen mixed ratings from analysts, including one "sell" and various "buy" recommendations.
• Institutional investors currently own 64.64% of Corbus Pharmaceuticals, reflecting significant interest and support from larger investment firms.

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $45.4286.

Several equities research analysts recently issued reports on CRBP shares. Weiss Ratings restated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, October 8th. Oppenheimer cut their price objective on shares of Corbus Pharmaceuticals from $56.00 to $53.00 and set an "outperform" rating for the company in a research report on Wednesday, August 6th. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Corbus Pharmaceuticals in a research report on Wednesday, September 17th. B. Riley upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 price objective for the company in a research report on Wednesday, July 30th. Finally, Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Saturday, July 12th.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Corton Capital Inc. acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter valued at about $86,000. Marshall Wace LLP acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter valued at about $137,000. Baker Avenue Asset Management LP acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter valued at about $138,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter valued at about $141,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter valued at about $186,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Stock Down 0.4%

Shares of NASDAQ CRBP opened at $16.25 on Wednesday. The firm has a 50-day simple moving average of $11.03 and a 200-day simple moving average of $8.76. The stock has a market capitalization of $199.23 million, a price-to-earnings ratio of -3.41 and a beta of 2.84. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $20.77.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) EPS for the quarter, beating analysts' consensus estimates of ($1.55) by $0.11. As a group, equities research analysts expect that Corbus Pharmaceuticals will post -4.23 EPS for the current year.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.